Should you buy JNJ stock?
- EPS: US$1.93 (down from US$2.36 in 1Q 2021).
- Revenue: US$23.4b (up 5.0% from 1Q 2021).
- Net income: US$5.15b (down 17% from 1Q 2021).
- Profit margin: 22% (down from 28% in 1Q 2021). Higher expenses drove the decrease in the margin.
Is JNJ stock a buy or sell?
With a beta of 0.71, JNJ is the definition of a defensive stock. While strong share price growth should not be expected from this behemoth, when one also considers its status as a dividend aristocrat, as well as its sterling financial profile, JNJ stands out as a stock for risk averse investors. I rate JNJ as a BUY.
Why is JNJ stock falling?
Shares of Johnson & Johnson ( NYSE:JNJ) were sinking by 5.9% as of 3:31 p.m. EDT on Friday after the healthcare giant announced a recall of a single lot of its Johnson's Baby Powder. J&J stated in ...
When will JNJ stock split?
Johnson & Johnson (JNJ) will split into two public companies within the next 18 to 24 months. One will get its many consumer brands, while the other will get its pharmaceuticals, medical devices,...
See more
Is JNJ stock a buy?
Johnson & Johnson - Hold Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of JNJ, demonstrate its potential to outperform the market. It currently has a Growth Score of B.
Is JNJ overvalued?
The intrinsic value of one JNJ stock under the Base Case scenario is 138.42 USD. Compared to the current market price of 178.23 USD, Johnson & Johnson is Overvalued by 22%.
What is the target price for JNJ?
Stock Price TargetsHigh$215.00Median$187.00Low$165.00Average$187.12Current Price$171.31
What is the highest JNJ stock has been?
Johnson & Johnson - 52 Year Stock Price History | JNJThe all-time high Johnson & Johnson stock closing price was 186.01 on April 25, 2022.The Johnson & Johnson 52-week high stock price is 186.69, which is 7.2% above the current share price.More items...
Is Johnson and Johnson going out of business?
J&J itself isn't bankrupt—instead, it has split off a new unit essentially designed to go broke paying legal liabilities. It's part of a maneuver to deal with about 38,000 lawsuits, mostly filed by women who claim one of the company's oldest products, baby powder, causes ovarian cancer.
Will JNJ ever split again?
The split isn't expected to happen until the end of 2023. Duato also told investors that the pandemic sped up trends like same-day delivery within the consumer health business.
How many times has Johnson and Johnson stock split?
According to our Johnson and Johnson stock split history records, Johnson and Johnson has had 6 splits.
What is the target price for Pfizer?
Stock Price TargetsHigh$75.00Median$55.00Low$49.00Average$56.67Current Price$51.12
Will PG stock go up?
The 21 analysts offering 12-month price forecasts for Procter & Gamble Co have a median target of 160.00, with a high estimate of 185.00 and a low estimate of 127.00. The median estimate represents a +11.79% increase from the last price of 143.12.
How often does Johnson and Johnson pay dividends?
4 dividends per yearDividend Summary There are typically 4 dividends per year (excluding specials), and the dividend cover is approximately 2.3.
Does Johnson and Johnson own Pfizer?
Johnson & Johnson announced yesterday that it was buying the Pfizer division, paying $16.6 billion to beat out several other bidders. Analysts said the move would make Johnson & Johnson the world's largest consumer health care company.
Why should I invest in JNJ?
Along with the results, JNJ also announced a hike in its quarterly dividend by 6.6%, to $1.13 per share. This marks the company's 60th consecutive yearly dividend increase. The company's efforts in growing its business through new innovative products and drugs are why I believe Johnson & Johnson is worth investing in.
What is Johnson & Johnson's stock symbol?
What other stocks do shareholders of Johnson & Johnson own?
Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."
What is Alex Gorsky's approval rating as Johnson & Johnson's CEO?
Based on aggregate information from My MarketBeat watchlists, some companies that other Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Walt Disney (DIS), NVIDIA (NVDA), Intel (INTC), JPMorgan Chase & Co. (JPM), Cisco Systems (CSCO), Procter & Gamble (PG) and AbbVie (ABBV).
How much money does Johnson & Johnson make?
2,535 employees have rated Johnson & Johnson CEO Alex Gorsky on Glassdoor.com. Alex Gorsky has an approval rating of 94% among Johnson & Johnson's employees. This puts Alex Gorsky in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
Where are Johnson & Johnson's headquarters?
Johnson & Johnson has a market capitalization of $410.59 billion and generates $93.78 billion in revenue each year . The company earns $20.88 billion in net income (profit) each year or $7.81 on an earnings per share basis.
What is the PEG ratio of Johnson and Johnson?
Johnson & Johnson is headquartered at ONE JOHNSON & JOHNSON PLZ , NEW BRUNSWICK N J, 08933.
What are Johnson and Johnson products?
Johnson & Johnson has a PEG Ratio of 2.34. PEG Ratios above 1 indicate that a company could be overvalued.
What is dividend percentage?
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands ; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Who owns restricted shares of a company?
A company's dividend expressed as a percentage of its current stock price.
What are J&J segments?
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
What is the pharmaceutical segment of Johnson and Johnson?
New Brunswick, NJ based J&J’s worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. In 2020, these segments contributed 55%, 38% and 17%, respectively, to the company’s total revenues of $82.6 billion (up 0.6%).
How many X is Zacks?
Pharmaceutical Segment – Johnson & Johnson has one of the most diverse revenue streams in the industry within the pharmaceutical division. The company has several multi-million-dollar drugs covering a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. Pharmaceutical sales in 2020 totaled $45.6 billion, up 8%.
How many sectors are there in Zacks?
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
What are the different grades for stocks?
The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank.
What is Johnson and Johnson's biggest strength?
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
Is ZacksTrade a separate company?
Johnson & Johnson’s biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. It comprises some 250 subsidiaries, which clearly means that the business is extremely well diversified. Its diversification helps it to withstand economic cycles more effectively. Meanwhile, J&J has one of the largest research and development (R&D) budget among pharma companies.#N#New Brunswick, NJ based J&J’s worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. In 2020, these segments contributed 55%, 38% and 17%, respectively, to the ...
Ownership
- Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol \"JNJ.\" Johnson & Johnson's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.04%), Northern Trust Corp (1.30%), Boston Partners (0.46%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), Swiss National Bank (0.37%) an…
Release
- Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, July 16th 2019. View Earnings Estimates for Johnson & Johnson.
Sales
- Johnson & Johnson issued an update on its FY19 earnings guidance on Tuesday, April, 16th. The company provided earnings per share (EPS) guidance of $8.53-8.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.59. The company issued revenue guidance of $80.4-81.2 billion, compared to the consensus revenue estimate of $81.17 …
Risks
- 11 brokerages have issued 1-year price targets for Johnson & Johnson's shares. Their forecasts range from $129.00 to $157.00. On average, they expect Johnson & Johnson's share price to reach $146.00 in the next year. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.
Ratings
- 11 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Johnson & Johnson in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of \"Buy.\" View Analyst Ratings for Johnson & Johnson.
Reviews
- News headlines about JNJ stock have been trending positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Johnson & Johnson ea…
Business
- Johnson & Johnson has a market capitalization of $368.09 billion and generates $81.58 billion in revenue each year. The company earns $15.30 billion in net income (profit) each year or $8.18 on an earnings per share basis. Johnson & Johnson employs 135,100 workers across the globe.